Abstract
Zerumbonoquinone 10 and zerumbonaminone 11 have been designed to release toxic moieties selectively and preferentially under reductive conditions. These compounds were synthesized by coupling the quinone delivery system with zerumbone alcohol 8 and amine 9. All compounds were evaluated for cytotoxicity against KB (non reductase overexpressing cells), NCI-H187 and MCF-7 (reductase overexpressing cells) and normal cells (Vero cells). Bioreductive compounds 10 and 11 were found to act as bioreductive anticancer agents exhibiting less cytotoxicity than the parents 8 and 9 in KB cells with good stability, and were partially bioreductively active against MCF-7 and NCI-H187 cells.
Keywords: Bioreductive, KB, NCI-H187, MCF-7, Zerumbone derivatives, Zingiber zerumbet Smith, Anticancer, sesquiterpene, antiproliferative, antileukemia, stereochemistry, tumor cells, tumor targeting drug delivery system (TDDS), intramolecular cyclization, non-toxic lactone species III
Letters in Drug Design & Discovery
Title: Anticancer Activity of the Bioreductive and Non-Bioreductive Zerumbone Derivatives
Volume: 8 Issue: 6
Author(s): Siripit Pitchuanchom, Uraiwan Songsiang, Natthida Weerapreeyakul and Chavi Yenjai
Affiliation:
Keywords: Bioreductive, KB, NCI-H187, MCF-7, Zerumbone derivatives, Zingiber zerumbet Smith, Anticancer, sesquiterpene, antiproliferative, antileukemia, stereochemistry, tumor cells, tumor targeting drug delivery system (TDDS), intramolecular cyclization, non-toxic lactone species III
Abstract: Zerumbonoquinone 10 and zerumbonaminone 11 have been designed to release toxic moieties selectively and preferentially under reductive conditions. These compounds were synthesized by coupling the quinone delivery system with zerumbone alcohol 8 and amine 9. All compounds were evaluated for cytotoxicity against KB (non reductase overexpressing cells), NCI-H187 and MCF-7 (reductase overexpressing cells) and normal cells (Vero cells). Bioreductive compounds 10 and 11 were found to act as bioreductive anticancer agents exhibiting less cytotoxicity than the parents 8 and 9 in KB cells with good stability, and were partially bioreductively active against MCF-7 and NCI-H187 cells.
Export Options
About this article
Cite this article as:
Pitchuanchom Siripit, Songsiang Uraiwan, Weerapreeyakul Natthida and Yenjai Chavi, Anticancer Activity of the Bioreductive and Non-Bioreductive Zerumbone Derivatives, Letters in Drug Design & Discovery 2011; 8 (6) . https://dx.doi.org/10.2174/157018011795906811
DOI https://dx.doi.org/10.2174/157018011795906811 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
miRNAs in the Biology of Cancers and Viral Infections
Current Medicinal Chemistry A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Drug Combinations Enhancing the Antineoplastic Effects of Erlotinib in High-Grade Glioma
Recent Patents on Anti-Cancer Drug Discovery Investigating the Impact of Different Acrylamide (Electrophilic Warhead) on Osimertinib’s Pharmacological Spectrum by Molecular Mechanic and Quantum Mechanic Approach
Combinatorial Chemistry & High Throughput Screening Genetic Instability Influences Drug Response in Cancer Cells
Current Drug Targets New Insights on the Antitumoral Properties of Prodiginines
Current Medicinal Chemistry Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities
Current Molecular Medicine Biochemical and Pharmacological Applications of Essential Oils in Human Health Especially in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Palliative Care for Chest Tumors – Hong Kong, France and Canada
Current Cancer Therapy Reviews Biological Evaluation of <sup>99m</sup>Tc-HYNIC-EDDA/tricine-(Ser)<sub>3</sub>-D4 Peptide for Tumor Targeting
Current Radiopharmaceuticals The Ovary Feels Fine when Paracrine and Autocrine Networks Cooperate with Gonadotropins in the Regulation of Folliculogenesis
Current Pharmaceutical Design Placebos Used in Clinical Trials for Chinese Herbal Medicine
Recent Patents on Inflammation & Allergy Drug Discovery Natural Compounds Containing a Condensed Cyclopropane Ring. Natural and Synthetic Aspects
Current Organic Chemistry Garlic-Derived Allyl Sulfides in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Image Fusion Based on Estimation Theory: Applied to PET/CT for Radiotherapy
Recent Patents on Medical Imaging The Tribbles-1 Protein in Humans: Roles and Functions in Health and Disease
Current Molecular Medicine Diversity of Anticancer and Antimicrobial Compounds from Lichens and Lichen-derived Fungi: A Systematic Review (1985-2017)
Current Organic Chemistry Paraneoplastic Neurological Syndromes - Diagnosis and Management
Current Pharmaceutical Design Wnt/β-Catenin/LEF-1 Signaling in Chronic Lymphocytic Leukemia (CLL): A Target for Current and Potential Therapeutic Options
Current Cancer Drug Targets Lycopene: A Review of Its Potential as an Anticancer Agent
Current Medicinal Chemistry - Anti-Cancer Agents